FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma By Ogkologos - May 20, 2026 36 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Oncolytic Virus Enables the Immune System to Attack Tumors October 12, 2023 Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in... May 20, 2021 Five Questions With…Jessica, Katie, and Melanie July 21, 2022 EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab August 11, 2022 Load more HOT NEWS Health inequalities: breaking down barriers to cancer screening Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... How to Cope with Appetite Loss in a Loved One With... Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with...
